Dr. David Barnes (MD) is an entrepreneurial physician-scientist who has partnered in the successful launch of several bio-medical research and development companies. Currently, Barnes holds executive officer and board level positions in a range of companies from small biotech start-ups to large public multinationals (e.g. Qu Biologics-Vancouver; PharmaGap Incorporated-Ottawa; NewLab Life Sciences-St. John’s; CSL Behring Incorporated-multinational). Barnes is a former clinical evaluator, Biologics and Genetic Therapies Directorate and former Head, Biotechnology Products Surveillance Unit, Marketed Health Products Directorate, Health Canada. Barnes is former Director, Clinical Drug Development, Children’s Hospital of Eastern Ontario Research Institute (Ottawa) and a former Investigator at the University of Ottawa Evidence Based Practice Center. A graduate of Memorial’s Faculty of Medicine, Barnes is an experienced physician, clinical researcher and molecular biologist who guest lectures in therapeutic product development, regulation and safety, with unique expertise in biotechnology, at several Canadian universities. He has provided company management, regulatory strategic, regulatory operational, medical officer, product development planning and regulatory submission development executive consulting services to small and large pharmaceutical, medical device, biotechnology and natural health product companies worldwide since 2000.
Mr. Russell Blacher is an experienced research and development professional for biologic drug compounds (peptide, protein and antibody). He has more than 25 years of experience in bridging the gap between research and development programs in a variety of corporate environments from virtual biotech start-ups to big pharma. He has successfully turned academic research discoveries into viable drug candidates and moved them through advanced clinical trials in both the U.S. and Europe and has actively participated in the programs of several currently marketed biopharmaceutical products: human insulin (Humulin®), Interferon Alpha (Roferon®), Interleukin-2 (Proleukin®), anti-CD11a (Raptiva®) and anti-EGFR (Vectibix®). He is knowledgeable in peptide synthesis, protein manufacturing and purification, analytical methods development and experienced in managing multiple outsourced contract manufacturing programs, process development/scale-up, analytical and biological testing laboratories as well as device development, clinical assay development, quality assurance and compliance and has authored the CMC section of regulatory submissions. Additionally, he is current in Good Manufacturing Practice (cGMP). Mr. Blacher has published more than 50 scientific papers in the related fields of protein chemistry and was most recently the Senior Director of Biopharmaceutical Development at MDS Pharma Services.
Dr. Wayne P. F. Gulliver currently serves as the Chair of the Discipline of Medicine, Faculty of Medicine, Memorial University of Newfoundland. He has extensive experience as a practicing dermatologist, an investigator in clinical trials and as an entrepreneur managing clinical research operations. He has 19 years of clinical practice and research in dermatology with a focus on psoriasis and genetics research. Dr. Gulliver has participated in or is currently supervising over 200 clinical trials covering many aspects of dermatology, 51 published papers and 28 abstracts. Dr. Wayne Gulliver is CSO of NewLab Clinical Research Inc. and CSO of Newfound Genomics and is a past member of the Governing Council of the National Research Council, and Vice President of the Canadian Dermatology Association (1997). He holds a Bachelor of Science (1978) and a Doctor of Medicine (1985) from Memorial University and completed his residency in dermatology at McGill University, (1989) Montreal.
|
|
|
|
|